Cargando…
Management of Cancer-Associated Myositis
PURPOSE OF THE REVIEW: Cancer-associated myositis (CAM) is defined as when cancer appears within 3 years of myositis onset. Dermatomyositis and seronegative immune–mediated necrotizing myopathy are the phenotypes mostly related to cancer. In general, treatment principles in myositis patients with an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589595/ https://www.ncbi.nlm.nih.gov/pubmed/36313478 http://dx.doi.org/10.1007/s40674-022-00197-2 |
_version_ | 1784814338572288000 |
---|---|
author | Selva-O’Callaghan, Albert Trallero-Araguás, Ernesto Ros, Javier Gil-Vila, Albert Lostes, Julia Agustí, Antonia Riera-Arnau, Judit Alvarado-Cárdenas, Marcelo Pinal-Fernandez, Iago |
author_facet | Selva-O’Callaghan, Albert Trallero-Araguás, Ernesto Ros, Javier Gil-Vila, Albert Lostes, Julia Agustí, Antonia Riera-Arnau, Judit Alvarado-Cárdenas, Marcelo Pinal-Fernandez, Iago |
author_sort | Selva-O’Callaghan, Albert |
collection | PubMed |
description | PURPOSE OF THE REVIEW: Cancer-associated myositis (CAM) is defined as when cancer appears within 3 years of myositis onset. Dermatomyositis and seronegative immune–mediated necrotizing myopathy are the phenotypes mostly related to cancer. In general, treatment principles in myositis patients with and without CAM are similar. However, some aspects of myositis management are particular to CAM, including (a) the need for a multidisciplinary approach and a close relationship with the oncologist, (b) the presence of immunosuppressive and antineoplastic drug interactions, and (c) the role of the long-term immunosuppressive therapy as a risk factor for cancer relapse or development of a second neoplasm. In this review, we will also discuss immunotherapy in patients treated with checkpoint inhibitors as a treatment for their cancer. RECENT FINDINGS: Studies on cancer risk in patients treated with long-term immunosuppressive drugs, in autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis, and in solid organ transplant recipients have shed some light on this topic. Immunotherapy, which has been a great advance for the treatment of some types of malignancy, may be also of interest in CAM, given the special relationship between both disorders. SUMMARY: Management of CAM is a challenge. In this complex scenario, therapeutic decisions must consider both diseases simultaneously. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40674-022-00197-2. |
format | Online Article Text |
id | pubmed-9589595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-95895952022-10-24 Management of Cancer-Associated Myositis Selva-O’Callaghan, Albert Trallero-Araguás, Ernesto Ros, Javier Gil-Vila, Albert Lostes, Julia Agustí, Antonia Riera-Arnau, Judit Alvarado-Cárdenas, Marcelo Pinal-Fernandez, Iago Curr Treatm Opt Rheumatol Other CTD: Inflammatory Myopathies and Sjogren's (I Pinal-Fernández, Section Editor) PURPOSE OF THE REVIEW: Cancer-associated myositis (CAM) is defined as when cancer appears within 3 years of myositis onset. Dermatomyositis and seronegative immune–mediated necrotizing myopathy are the phenotypes mostly related to cancer. In general, treatment principles in myositis patients with and without CAM are similar. However, some aspects of myositis management are particular to CAM, including (a) the need for a multidisciplinary approach and a close relationship with the oncologist, (b) the presence of immunosuppressive and antineoplastic drug interactions, and (c) the role of the long-term immunosuppressive therapy as a risk factor for cancer relapse or development of a second neoplasm. In this review, we will also discuss immunotherapy in patients treated with checkpoint inhibitors as a treatment for their cancer. RECENT FINDINGS: Studies on cancer risk in patients treated with long-term immunosuppressive drugs, in autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis, and in solid organ transplant recipients have shed some light on this topic. Immunotherapy, which has been a great advance for the treatment of some types of malignancy, may be also of interest in CAM, given the special relationship between both disorders. SUMMARY: Management of CAM is a challenge. In this complex scenario, therapeutic decisions must consider both diseases simultaneously. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40674-022-00197-2. Springer International Publishing 2022-10-21 2022 /pmc/articles/PMC9589595/ /pubmed/36313478 http://dx.doi.org/10.1007/s40674-022-00197-2 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Other CTD: Inflammatory Myopathies and Sjogren's (I Pinal-Fernández, Section Editor) Selva-O’Callaghan, Albert Trallero-Araguás, Ernesto Ros, Javier Gil-Vila, Albert Lostes, Julia Agustí, Antonia Riera-Arnau, Judit Alvarado-Cárdenas, Marcelo Pinal-Fernandez, Iago Management of Cancer-Associated Myositis |
title | Management of Cancer-Associated Myositis |
title_full | Management of Cancer-Associated Myositis |
title_fullStr | Management of Cancer-Associated Myositis |
title_full_unstemmed | Management of Cancer-Associated Myositis |
title_short | Management of Cancer-Associated Myositis |
title_sort | management of cancer-associated myositis |
topic | Other CTD: Inflammatory Myopathies and Sjogren's (I Pinal-Fernández, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589595/ https://www.ncbi.nlm.nih.gov/pubmed/36313478 http://dx.doi.org/10.1007/s40674-022-00197-2 |
work_keys_str_mv | AT selvaocallaghanalbert managementofcancerassociatedmyositis AT tralleroaraguasernesto managementofcancerassociatedmyositis AT rosjavier managementofcancerassociatedmyositis AT gilvilaalbert managementofcancerassociatedmyositis AT lostesjulia managementofcancerassociatedmyositis AT agustiantonia managementofcancerassociatedmyositis AT rieraarnaujudit managementofcancerassociatedmyositis AT alvaradocardenasmarcelo managementofcancerassociatedmyositis AT pinalfernandeziago managementofcancerassociatedmyositis |